{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:18:54Z","timestamp":1791425934105,"version":"4.3.3"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,2,1]]},"DOI":"10.1093\/jac\/dku422","type":"journal-article","created":{"date-parts":[[2014,11,12]],"date-time":"2014-11-12T04:40:45Z","timestamp":1415767245000},"page":"518-527","source":"Crossref","is-referenced-by-count":61,"title":["Nitroimidazo-oxazole compound DNDI-VL-2098: an orally effective preclinical drug candidate for the treatment of visceral leishmaniasis"],"prefix":"10.1093","volume":"70","author":[{"given":"Suman","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Yardley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preeti","family":"Vishwakarma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Shivahare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhawna","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Launay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil K.","family":"Puri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,11,10]]},"reference":[{"key":"key\n\t\t\t\t20170425183753_DKU422C1","author":"WHO"},{"key":"key\n\t\t\t\t20170425183753_DKU422C2","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1128\/CMR.18.2.293-305.2005","article-title":"Subversion mechanisms by which Leishmania parasites can escape the host immune response: a signaling point of view","volume":"18","year":"2005","journal-title":"Clin Microbiol Rev"},{"key":"key\n\t\t\t\t20170425183753_DKU422C3","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1111\/j.1469-0691.2011.03635.x","article-title":"Leishmaniasis impact and treatment access","volume":"17","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t20170425183753_DKU422C4","author":"Drugs for Neglected Diseases initiative"},{"key":"key\n\t\t\t\t20170425183753_DKU422C5","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1128\/CMR.14.1.150-164.2001","article-title":"Drug targets and mechanisms of resistance in the anaerobic protozoa","volume":"14","year":"2001","journal-title":"Clin Microbiol Rev"},{"key":"key\n\t\t\t\t20170425183753_DKU422C6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2307\/3280774","article-title":"Therapeutic efficacy of several nitroimidazoles for experimental Trypanosoma cruzi infections in mice","volume":"67","year":"1981","journal-title":"J Parasitol"},{"key":"key\n\t\t\t\t20170425183753_DKU422C7","doi-asserted-by":"crossref","first-page":"6563","DOI":"10.1021\/jm200377r","article-title":"Synthesis and structure-activity relationships of varied ether linker analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine (PA-824)","volume":"54","year":"2011","journal-title":"J Med Chem"},{"key":"key\n\t\t\t\t20170425183753_DKU422C8","author":"TB Alliance","year":"2003"},{"key":"key\n\t\t\t\t20170425183753_DKU422C9","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3797\/scipharm.0907-14","article-title":"Synthetic nitroimidazoles: biological activities and mutagenicity relationships","volume":"77","year":"2009","journal-title":"Sci Pharm"},{"key":"key\n\t\t\t\t20170425183753_DKU422C10","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/B978-012775390-4\/50233-5","article-title":"Animal models of visceral leishmaniasis","volume-title":"Handbook of Animal Models of Infection","year":"1999"},{"key":"key\n\t\t\t\t20170425183753_DKU422C11","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1021\/jm401893j","article-title":"Synthesis, structure-activity relationships and biological studies of chromenochalcones as potential antileishmanial agents","volume":"57","year":"2014","journal-title":"J Med Chem"},{"key":"key\n\t\t\t\t20170425183753_DKU422C12","doi-asserted-by":"crossref","first-page":"4608","DOI":"10.1128\/AAC.02343-12","article-title":"Antileishmanial activity, uptake, and biodistribution of an amphotericin B and poly(\u03b1-glutamic acid) complex","volume":"57","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170425183753_DKU422C13","doi-asserted-by":"crossref","first-page":"5602","DOI":"10.1128\/AAC.00246-11","article-title":"Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness","volume":"55","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170425183753_DKU422C14","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1128\/AAC.00985-10","article-title":"Antileishmanial and antitrypanosomal activities of the 8-aminoquinoline tafenoquine","volume":"54","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170425183753_DKU422C15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","year":"1983","journal-title":"J Immunol Methods"},{"key":"key\n\t\t\t\t20170425183753_DKU422C16","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0001-706X(93)90083-N","article-title":"A comparison of three methods of estimating EC50 in studies of drug resistance of malaria parasites","volume":"55","year":"1993","journal-title":"Acta Trop"},{"key":"key\n\t\t\t\t20170425183753_DKU422C17","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1128\/AAC.46.3.929-931.2002","article-title":"In vivo activities of farnesyl pyrophosphate synthase inhibitors against Leishmania donovani and Toxoplasma gondii","volume":"46","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170425183753_DKU422C18","doi-asserted-by":"crossref","first-page":"e94596","DOI":"10.1371\/journal.pone.0094596","article-title":"Combination of liposomal CpG oligodeoxynucleotide 2006 and miltefosine induces strong cell-mediated immunity during experimental visceral leishmaniasis","volume":"9","year":"2014","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20170425183753_DKU422C19","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/jac\/dkr485","article-title":"Treatment of Leishmania donovani-infected hamsters with miltefosine: analysis of cytokine mRNA expression by real-time PCR, lymphoproliferation, nitrite production and antibody responses","volume":"67","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170425183753_DKU422C20","doi-asserted-by":"crossref","first-page":"e525","DOI":"10.1016\/j.ijid.2011.03.021","article-title":"Recent advances in leishmaniasis treatment","volume":"15","year":"2011","journal-title":"Int J Infect Dis"},{"key":"key\n\t\t\t\t20170425183753_DKU422C21","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/j.1469-0691.2011.03630.x","article-title":"Leishmaniasis chemotherapy\u2014challenges and opportunities","volume":"17","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t20170425183753_DKU422C22","first-page":"119re1","article-title":"The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis","volume":"4","year":"2012","journal-title":"Sci Transl Med"},{"key":"key\n\t\t\t\t20170425183753_DKU422C23","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1128\/AAC.00722-13","article-title":"The R enantiomer of the antitubercular drug PA-824 as a potential oral treatment for visceral leishmaniasis","volume":"57","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170425183753_DKU422C24","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.micpath.2004.11.002","article-title":"Immunopathogenesis of infection with the visceralizing Leishmania species","volume":"38","year":"2005","journal-title":"Microb Pathog"},{"key":"key\n\t\t\t\t20170425183753_DKU422C25","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.4049\/jimmunol.166.3.1912","article-title":"The hamster as a model of human visceral leishmaniasis: progressive disease and impaired generation of nitric oxide in the face of a prominent Th1-like cytokine response","volume":"166","year":"2001","journal-title":"J Immunol"},{"key":"key\n\t\t\t\t20170425183753_DKU422C26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1297-9716-42-39","article-title":"Mechanisms of resistance and susceptibility to experimental visceral leishmaniosis: BALB\/c mouse versus Syrian hamster model","volume":"42","year":"2011","journal-title":"Vet Res"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","deposited":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T00:00:09Z","timestamp":1498176009000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article-lookup\/doi\/10.1093\/jac\/dku422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,10]]},"references-count":26,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2014,11,10]]},"published-print":{"date-parts":[[2015,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dku422","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,10]]}}}